Meropenem for children with severe pneumonia: Protocol for a randomized controlled trial

. 2022 Nov 17;13:1021661.

doi: 10.3389/fphar.2022.1021661.

eCollection 2022.


Item in Clipboard

Xue Tian et al.

Front Pharmacol.



Background: Pneumonia, caused by infection or other factors, seriously endangers the health of children. Meropenem is an effective broad-spectrum antibiotic using in the treatment of infectious diseases. In the therapy of pneumonia, meropenem is mostly employed for the treatment of moderate to severe pneumonia. Previously, we established a population pharmacokinetics (PPK) model for meropenem in pediatric severe infection and simulated the control rate of the time during which the free plasma concentration of meropenem exceeds the minimum inhibitory concentration (MIC) is 70% of the dosing interval (70% fT > MIC). Therefore, we plan to conduct a multicenter randomized controlled trial (RCT) to compare the efficacy and safety between conventional regimen and model regimen for meropenem in pediatric severe pneumonia. Methods: One hundred patients (aged 3 months to 15 years) will be recruited in this RCT. They will be assigned randomly (at a 1:1 ratio) to a conventional treatment group (20 mg/kg, q8h, with 0.5-1 h infusion) and a model treatment group (20 mg/kg, q8 h, with 4 h infusion). The primary outcome will be 70% fT > MIC. Secondary outcomes will be the prevalence of meropenem therapy failure, duration of antibiotic therapy, changes in levels of inflammatory indicators, changes in imaging examination results, and prevalence of adverse events. Ethical approval of our clinical trial has been granted by the ethics committee of Beijing Children’s Hospital ([2022]-E-133-Y). This trial has been registered in the Chinese Clinical Trial Registry (ChiCTR2200061207). Discussion: Based on our previous PPK data, we have designed this RCT. It is hoped that it will promote rational use of antibacterial drugs in children suffering from severe pneumonia. Clinical Trial Registration: http://www.chictr.org.cn identifier, ChiCTR2200061207.


children; meropenem; randomized controlled trial; severe pneumonia; study protocol.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.



The schematic diagram of the RCT design.


    1. Baldwin C. M., Lyseng-Williamson K. A., Keam S. J. (2008). Meropenem: A review of its use in the treatment of serious bacterial infections. Drugs 68 (6), 803–838. 10.2165/00003495-200868060-00006



    1. Cies J. J., Moore W. N., Enache A., Chopra A. (2017). Population pharmacokinetics and pharmacodynamic target attainment of meropenem in critically ill young children. J. Pediatr. Pharmacol. Ther. 22 (4), 276–285. 10.5863/1551-6776-22.4.276




    1. Clsi (2019). Performance standards for antimicrobial susceptibility testing. 29th ed. Tanzania, Ukraine: Clinical And Laboratory Standards Institute.

    1. de Benedictis F. M., Kerem E., Chang A. B., Colin A. A., Zar H. J., Bush A. (2020). Complicated pneumonia in children. Lancet 396 (10253), 786–798. 10.1016/S0140-6736(20)31550-6



    1. Fine M. J., Auble T. E., Yealy D. M., Hanusa B. H., Weissfeld L. A., Singer D. E., et al. (1997). A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. Med. 336 (4), 243–250. 10.1056/NEJM199701233360402



Source link

Back to top button